Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT04369534

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04369534
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Croatia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04369534. Randomized; no masking; primary purpose treatment. Start 2015-12-01 (actual); primary completion 2019-11-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction
Acronym
SPARELIFE
Condition
Acute Coronary Syndrome
Condition
STEMI
Condition
NSTEMI - Non-ST Segment Elevation MI
Condition
PLATELET AGGREGATION
Condition
INDIVIDUALIZED THERAPY
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Ticagrelor
Lead sponsor
University of Zagreb (class: other)
Collaborator
Croatian Science Foundation (class: other government)
Collaborator
Clinical Hospital Centre Zagreb (class: other)

Record details

Record id
cardio:ct-nct04369534
Content hash
a950f7ac84735311e4ee6c4337111df27326d836113df40d98b483d1745edbf3